文献速递精神分裂症与精神病性障碍

精神分裂症可重复的表观遗传风险特征与脑甲基化及功能的相关性

Association of a Reproducible Epigenetic Risk Profile for Schizophrenia With Brain Methylation and Function.
PubMed 文献 · JAMA Psychiatry · 2020-01-01

该病例对照研究基于6个独立队列2230份全血DNA甲基化数据,用机器学习构建精神分裂症多甲基化评分(PMS),并在死后DLPFC样本中验证。PMS可区分精神分裂症(AUC 0.69–0.78)且具疾病特异性,并与健康对照工作记忆时DLPFC-HC连接改变相关。

要点

  • 血源PMS在3个独立数据集可区分精神分裂症,AUC 0.69–0.78。
  • PMS在死后DLPFC样本中亦见差异(AUC=0.63),且对双相、抑郁、孤独症不显著。
  • 健康对照中类精神分裂症PMS与工作记忆时DLPFC-HC连接改变相关。

核心结论

  • 识别出可重复且对精神分裂症特异的血DNA甲基化特征,与工作记忆时DLPFC-HC功能耦合改变相关,并对应死后DLPFC甲基化差异。

研究设计与样本

  • 2008–2018年在德国、英国、美国、澳大利亚开展的病例对照研究,分析6个独立队列2230份全血DNA甲基化数据(健康对照1238例、精神分裂症803例等)。
  • 另分析244份死后DLPFC样本(健康对照136例、精神分裂症108例)的DNA甲基化数据。
  • 393名健康对照有神经影像和全基因组关联数据,用于计算精神分裂症多基因风险评分(PRS)。

主要发现

  • PMS在3个独立数据集与精神分裂症相关(AUC 0.69–0.78;P值0.049至1.24×10-7)。
  • PMS与死后DLPFC样本相关(AUC=0.63;P=1.42×10-4),但与重性抑郁(AUC=0.51;P=.16)、孤独症(AUC=0.53;P=.66)、双相障碍(AUC=0.58;P=.21)无显著相关。
  • 对分类贡献最大的通路包括突触过程。
  • 健康对照中类精神分裂症PMS者DLPFC-HC连接显著改变(验证甲基化/MRI:t<-3.81,FWE校正P<.04;验证MRI:t<-3.54,FWE校正P<.02)。
  • PMS与PRS交互作用与DLPFC-HC连接无显著相关(P>.19)。

关键数值与推荐

  • PMS区分精神分裂症的AUC范围为0.69–0.78(3个独立数据集)。
  • 死后DLPFC样本中PMS区分精神分裂症的AUC=0.63(P=1.42×10-4)。
  • PMS与重性抑郁、孤独症、双相障碍的AUC分别为0.51、0.53、0.58,均不显著。

临床怎么用

  • PMS作为潜在表观遗传生物标志物,可能有助于精神分裂症的多模态分层和个体化治疗研究。
  • 血源PMS与脑功能连接及死后脑甲基化关联,提示其可反映精神分裂症中间表型。

局限性

  • 原文未明确报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Schizophrenia is a severe mental disorder in which epigenetic mechanisms may contribute to illness risk. Epigenetic profiles can be derived from blood cells, but to our knowledge, it is unknown whether these predict established brain alterations associated with schizophrenia. OBJECTIVE: To identify an epigenetic signature (quantified as polymethylation score [PMS]) of schizophrenia using machine learning applied to genome-wide blood DNA-methylation data; evaluate whether differences in blood-derived PMS are mirrored in data from postmortem brain samples; test whether the PMS is associated with alterations of dorsolateral prefrontal cortex hippocampal (DLPFC-HC) connectivity during working memory in healthy controls (HC); explore the association between interactions between polygenic and epigenetic risk with DLPFC-HC connectivity; and test the specificity of the signature compared with other serious psychiatric disorders. DESIGN, SETTING, AND PARTICIPANTS: In this case-control study conducted from 2008 to 2018 in sites in Germany, the United Kingdom, the United States, and Australia, blood DNA-methylation data from 2230 whole-blood samples from 6 independent cohorts comprising HC (1238 [55.5%]) and participants with schizophrenia (803 [36.0%]), bipolar disorder (39 [1.7%]), major depressive disorder 35 [1.6%]), and autism (27 [1.2%]), and first-degree relatives of all patient groups (88 [3.9%]) were analyzed. DNA-methylation data were further explored from 244 postmortem DLPFC samples from 136 HC and 108 patients with schizophrenia. Neuroimaging and genome-wide association data were available for 393 HC. The latter data was used to calculate a polygenic risk score (PRS) for schizophrenia. The data were analyzed in 2019. MAIN OUTCOMES AND MEASURES: The accuracy of schizophrenia control classification based on machine learning using epigenetic data; association of schizophrenia PMS scores with DLPFC-HC connectivity; and association of the interaction between PRS and PMS with DLPFC-HC connectivity. RESULTS: This study included 7488 participants (4395 men [58.7%]), of whom 3158 (2230 men [70.6%]) received a diagnosis of schizophrenia. The PMS signature was associated with schizophrenia across 3 independent data sets (area under the curve [AUC] from 0.69 to 0.78; P value from 0.049 to 1.24 × 10-7) and data from postmortem DLPFC samples (AUC = 0.63; P = 1.42 × 10-4), but not with major depressive disorder (AUC = 0.51; P = .16), autism (AUC = 0.53; P = .66), or bipolar disorder (AUC = 0.58; P = .21). Pathways contributing most to the classification included synaptic processes. Healthy controls with schizophrenia-like PMS showed significantly altered DLPFC-HC connectivity (validation methylation/magnetic resonance imaging, t < -3.81; P for familywise error, <.04; validation magnetic resonance imaging, t < -3.54; P for familywise error, <.02), mirroring the lack of functional decoupling in schizophrenia. There was no significant association of the interaction between PMS and PRS with DLPFC-HC connectivity (P > .19). CONCLUSIONS AND RELEVANCE: We identified a reproducible blood DNA-methylation signature specific for schizophrenia that was correlated with altered functional DLPFC-HC coupling during working memory and mapped to methylation differences found in DLPFC postmortem samples. This indicates a possible epigenetic contribution to a schizophrenia intermediate phenotype and suggests that PMS could be of interest to be studied in the context of multimodal biomarkers for disease stratification and treatment personalization.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Chen J, Zang Z, Braun U, et al. Association of a Reproducible Epigenetic Risk Profile for Schizophrenia With Brain Methylation and Function. JAMA Psychiatry. 2020. PMID: 32049268. doi:10.1001/jamapsychiatry.2019.4792

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。